Articles tagged with Osteosarcoma
Researchers found that Bortezomib shuts down cellular machines that destroy Runx2, a protein complex that blocks the growth of bone cancer cells. The study suggests that Bortezomib may represent a new treatment option for osteosarcoma, a devastating disease that responds poorly to current chemotherapies.
A new therapeutic target has been identified for osteosarcoma, a type of bone cancer that affects about 30% of patients despite existing treatments. The protein interleukin-11 receptor alpha (IL-11Ra) is highly expressed in primary osteosarcoma and lung metastases from these tumors.
Researchers have discovered genetic variants that can help personalize treatment for infant osteosarcoma, leading to improved survival rates and reduced toxicity. The study, which analyzed data from 100 patients, found that specific genetic variants are associated with greater methotrexate toxicity and better therapeutic effects.
Researchers have developed a high-fidelity animal model of osteosarcoma by genetically modifying mice to lack the p53 and Rb tumor suppressor genes. This model closely recapitulates human osteosarcomagenesis, providing valuable insights into the disease's genetic contributions.
A four-year study on pediatric osteosarcoma will investigate the effects of genes related to bone growth and lifestyle habits. The research team hopes to find a link between bone growth genes and the development of osteosarcoma in children.
A randomized trial found that increasing chemotherapy dose intensity did not improve survival rates in patients with osteosarcoma. However, the dose-intensive regimen showed better tumor cell death and lower risks of certain side effects. The study challenges the use of histologic response as a key predictor factor for treatment outcomes.
A retrospective study from St. Jude Children's Research Hospital found that high levels of telomerase gene expression are associated with an unfavorable outcome for children treated for osteosarcoma, including lower progression-free survival rates and decreased overall survival.
Osteosarcoma survival rates have remained unchanged for 20 years, with only 54% of patients alive after five years. The Teenage Cancer Trust is urging more research to develop effective new treatments that prioritize patient well-being. Delays in diagnosis and non-specific symptoms make it challenging to treat the disease successfully.
Researchers identified a link between specific genetic mutations and increased risk of osteosarcoma, a type of bone cancer. They also developed a non-invasive method to measure thymidylate synthase inhibition using carbon-labeled thymidine PET scanning.
The study found that higher initial FDG uptake in tumor was associated with poorer prognosis in osteosarcoma patients. Patients identified as having high FDG uptake could be treated more aggressively to improve outcomes.